Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

[1]  L. Wilhelmsen,et al.  The Multifactor Primary Prevention Trial in Göteborg, Sweden , 2012, Drugs.

[2]  K. Swedberg,et al.  Rationale and design of a randomized, double‐blind, placebo‐controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial (SHIFT) , 2010, European journal of heart failure.

[3]  Colin Simpson,et al.  Long-Term Trends in First Hospitalization for Heart Failure and Subsequent Survival Between 1986 and 2003: A Population Study of 5.1 Million People , 2009, Circulation.

[4]  K. Swedberg,et al.  Adequacy of diagnosis and treatment of chronic heart failure in primary health care in Sweden , 2009, European journal of heart failure.

[5]  K. Swedberg,et al.  Survival trends in men and women with heart failure of ischaemic and non-ischaemic origin: data for the period 1987-2003 from the Swedish Hospital Discharge Registry. , 2008, European heart journal.

[6]  P. Armstrong,et al.  Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. , 2009, Annals of internal medicine.

[7]  K. Swedberg,et al.  Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. , 2008, Journal of the American College of Cardiology.

[8]  Michael Böhm,et al.  Kommentar zu den ESC-Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 , 2008, European journal of heart failure.

[9]  R. Ferrari,et al.  Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial , 2008, The Lancet.

[10]  R. Ferrari,et al.  Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[11]  B. Billah,et al.  Analysis of randomized controlled trials on the effect of magnitude of heart rate reduction on clinical outcomes in patients with systolic chronic heart failure receiving beta-blockers. , 2008, The American journal of cardiology.

[12]  A. Camm,et al.  If Inhibition with Ivabradine , 2008 .

[13]  A. Camm,et al.  I f inhibition with ivabradine : electrophysiological effects and safety. , 2008, Drug safety.

[14]  M. Komajda,et al.  Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey , 2007, European journal of heart failure.

[15]  D. DiFrancesco.  Funny channels in the control of cardiac rhythm and mode of action of selective blockers. , 2006, Pharmacological research.

[16]  Salim Yusuf,et al.  Predictors of mortality and morbidity in patients with chronic heart failure. , 2006, European heart journal.

[17]  A. Hoes,et al.  Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.

[18]  Jean-Claude Tardif,et al.  Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. , 2005, European heart journal.

[19]  P. Poole‐Wilson,et al.  Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET. , 2005, American heart journal.

[20]  J. Udelson.  Ventricular remodeling in heart failure and the effect of beta-blockade. , 2004, The American journal of cardiology.

[21]  J. Udelson.  Ventricular remodeling in heart failure and the effect of beta-blockade. , 2004, The American journal of cardiology.

[22]  N. Freemantle,et al.  The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. , 2003, European heart journal.

[23]  J. Petruk-Kowalczyk.  [Beta-blockers in chronic heart failure]. , 2003, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego.

[24]  K. Swedberg,et al.  &bgr;-Blockers in Chronic Heart Failure , 2003, Circulation.

[25]  D. DeMets,et al.  Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study , 2002, Circulation.

[26]  PhilippeLechat,et al.  Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial , 2001 .

[27]  A. Mallet,et al.  Heart Rate and Cardiac Rhythm Relationships With Bisoprolol Benefit in Chronic Heart Failure in CIBIS II Trial , 2001, Circulation.

[28]  Fach,et al.  Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.

[29]  K. Swedberg,et al.  Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy , 1993, The Lancet.

[30]  A. Katz,et al.  The myocardium in congestive heart failure. , 1989, The American journal of cardiology.